Nuphar Luteum Root

Dosage for Nuphar Luteum Root must be highly individualized based on the patient's clinical response, serum testosterone levels, and the specific condition being treated.

• For Male Hypogonadism: The typical starting dose for standardized oral Nuphar Luteum Root extract is 100 mg to 200 mg daily, taken in one or two divided doses. Your healthcare provider will likely measure your serum testosterone levels after 2 to 4 weeks of therapy to adjust the dose. The maintenance dose generally ranges from 50 mg to 400 mg daily.
• For Muscle Wasting (Off-label): Clinical studies have utilized doses of 200 mg to 300 mg daily to promote nitrogen retention and increase lean body mass.
• Topical Gel Application: If using the 1% gel, the standard dose is 5 grams of gel (containing 50 mg of NLR extract) applied once daily to clean, dry, intact skin of the shoulders, upper arms, or abdomen.

Nuphar Luteum Root is generally not recommended for use in children under the age of 18 unless specifically prescribed by a pediatric endocrinologist for the treatment of delayed puberty.

• For Delayed Puberty: If deemed appropriate, low-dose therapy starting at 25 mg to 50 mg daily may be initiated. Close monitoring of bone age (via X-ray) is mandatory every 6 months to ensure that the drug does not cause premature closure of the epiphyseal plates (growth plates), which could result in permanent short stature.

Renal Impairment

No specific dosage adjustments are typically required for patients with mild to moderate renal impairment. However, because androgens can promote water and sodium retention, patients with severe renal disease or end-stage renal disease (ESRD) must be monitored closely for edema (swelling) and worsening of hypertension. Use with extreme caution in patients with a GFR below 30 mL/min.

Hepatic Impairment

Nuphar Luteum Root undergoes significant hepatic metabolism. In patients with mild hepatic impairment (Child-Pugh Class A), no initial dose adjustment is necessary, but liver function tests (LFTs) should be monitored. In patients with moderate to severe hepatic impairment (Child-Pugh Class B or C), the use of NLR is generally contraindicated due to the increased risk of hepatotoxicity and drug accumulation.

Elderly Patients

Clinical data suggest that elderly patients (over 65 years of age) may be more sensitive to the effects of androgens. There is an increased risk of prostatic hyperplasia (enlarged prostate) and prostatic carcinoma in this population. Healthcare providers typically start elderly patients at the lower end of the dosing spectrum (e.g., 50 mg daily) and monitor prostate-specific antigen (PSA) levels frequently.

• Oral Administration: Take the capsules at the same time each day. It is highly recommended to take Nuphar Luteum Root with a meal containing some fat (e.g., avocado, nuts, or dairy) to maximize absorption. Swallow the capsules whole; do not crush or chew them, as this may alter the release profile.
• Topical Administration: Apply the gel at the same time each morning. Wash your hands thoroughly with soap and water immediately after application to prevent accidental transfer of the medication to others (especially women and children). Cover the application site with clothing once the gel has dried.
• Storage: Store all forms of Nuphar Luteum Root at room temperature (20°C to 25°C or 68°F to 77°F). Keep the medication in its original container, away from moisture, heat, and direct sunlight.

If you miss a dose of Nuphar Luteum Root, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up. Consistent levels are necessary for the best therapeutic effect.

Symptoms of an acute overdose of Nuphar Luteum Root may include severe nausea, priapism (a painful, prolonged erection lasting more than 4 hours), extreme irritability, and sudden increases in blood pressure. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on cardiovascular monitoring and managing specific symptoms like priapism, which requires urgent urological intervention.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as sudden discontinuation can lead to withdrawal symptoms or a return of your original condition.

Patients taking Nuphar Luteum Root frequently report side effects related to its androgenic activity. These are often dose-dependent and may include:

• Acne and Oily Skin: Increased sebum production can lead to breakouts on the face, back, and chest. This typically begins within the first month of therapy.
• Fluid Retention (Edema): You may notice swelling in your ankles, feet, or hands. This is due to the drug's effect on sodium and water balance in the kidneys.
• Mood Changes: Some patients experience increased irritability, nervousness, or mild aggression (sometimes referred to as 'roid rage' in extreme cases).
• Injection Site Reactions: For those using the injectable form, redness, pain, or swelling at the site of the shot is common.

• Gynecomastia: The development of breast tissue in men. This occurs because a small portion of the androgenic alkaloids may be converted into estrogens through a process called aromatization.
• Sleep Apnea: Androgens can worsen or trigger obstructive sleep apnea, particularly in patients who are overweight or have pre-existing respiratory issues.
• Increased Hematocrit: An increase in the percentage of red blood cells, which can make the blood 'thicker' and increase the risk of clots.
• Decreased HDL Cholesterol: A reduction in 'good' cholesterol levels, which may impact long-term cardiovascular health.

• Hepatotoxicity: Rare cases of liver injury, characterized by elevated liver enzymes or jaundice (yellowing of the skin/eyes).
• Peliosis Hepatis: A condition where blood-filled cysts form in the liver; this is a very rare but serious complication associated with long-term androgen use.
• Azoospermia: A complete absence of sperm in the semen, which can lead to infertility. This occurs because exogenous androgens suppress the body's natural production of follicle-stimulating hormone (FSH).

> Warning: Stop taking Nuphar Luteum Root and call your doctor immediately if you experience any of the following serious symptoms:

• Cardiovascular Events: Chest pain, shortness of breath, sudden weakness on one side of the body, or difficulty speaking. These may be signs of a heart attack or stroke.
• Venous Thromboembolism (VTE): Pain, swelling, or redness in one leg (Deep Vein Thrombosis) or sudden chest pain and coughing up blood (Pulmonary Embolism).
• Priapism: A painful erection that lasts longer than 4 hours. This is a medical emergency that can lead to permanent tissue damage if not treated.
• Severe Hepatic Dysfunction: Dark urine, pale stools, severe abdominal pain, or intense itching.
• Anaphylaxis: Hives, swelling of the face or throat, and difficulty breathing.

Prolonged use of Nuphar Luteum Root (typically defined as use exceeding 6-12 months) requires careful monitoring for chronic issues. These include permanent changes in lipid profiles, potential increases in prostate volume (BPH), and the risk of developing polycythemia (excessive red blood cells). There is also the potential for psychological dependence or 'Androgen Use Disorder' if the medication is misused for non-medical purposes (e.g., bodybuilding).

Secondary Exposure Risk (For Topical Gel):

As of the 2026 clinical labeling, Nuphar Luteum Root topical products carry a black box warning regarding the risk of virilization in children and women. Virilization is the development of male physical characteristics. In children, signs include enlarged genitalia, premature development of pubic hair, increased erections, and aggressive behavior. In women, it may include deepening of the voice, clitoral enlargement, and abnormal hair growth. To minimize this risk, patients must strictly follow application and washing protocols.

Cardiovascular and Hepatic Risk:

Some formulations may carry warnings regarding the increased risk of myocardial infarction (heart attack) and stroke, as well as the potential for peliosis hepatis and liver failure with high-dose or long-term oral use.

Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular blood work is necessary to ensure the medication is not causing silent damage to your organs.

Nuphar Luteum Root is a potent hormonal agent that must be used only under strict medical supervision. It is not intended for use by individuals seeking to enhance athletic performance or body composition in the absence of a diagnosed medical condition. Misuse of androgens can lead to severe, irreversible health consequences, including heart disease, liver failure, and psychiatric disturbances.

No FDA black box warnings for Nuphar Luteum Root capsules have been issued as of early 2026, though the Topical Gel formulation carries a specific warning regarding Secondary Exposure. This warning states that accidental transfer of the gel to children or women can cause serious virilization (development of male characteristics). Patients must cover the application site and wash their hands immediately after use. If a woman or child comes into contact with the application site, the area of contact should be washed with soap and water immediately.

• Allergic Reactions: While rare, anaphylaxis (severe allergic reaction) can occur. Patients with a known hypersensitivity to the Nuphar genus or any components of the formulation should avoid this drug.
• Hepatotoxicity: There is a risk of drug-induced liver injury. Patients should have baseline liver function tests (LFTs) and periodic monitoring during therapy. Symptoms such as jaundice, dark urine, or right upper quadrant pain should be reported immediately.
• Cardiovascular Risk: Androgen therapy may increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction and stroke. This risk is higher in patients with pre-existing heart disease or multiple cardiovascular risk factors (e.g., smoking, hypertension, diabetes).
• Prostate Health: Androgens can stimulate the growth of the prostate gland. Patients must be screened for prostate cancer before starting therapy and monitored with digital rectal exams (DRE) and PSA tests during treatment.
• Polycythemia: NLR can stimulate the production of red blood cells. An excessively high hematocrit (above 54%) increases blood viscosity and the risk of blood clots. Hematocrit levels must be monitored every 3 to 6 months.

To ensure safety, your healthcare provider will require regular laboratory testing:

• Total Testosterone: To ensure levels are within the therapeutic range.
• Complete Blood Count (CBC): Specifically monitoring hemoglobin and hematocrit.
• Liver Function Tests (LFTs): ALT, AST, and Bilirubin levels.
• Lipid Panel: Monitoring for decreases in HDL and increases in LDL cholesterol.
• Prostate-Specific Antigen (PSA): For men over 40-50 years of age to monitor for prostate changes.

Nuphar Luteum Root generally does not impair the ability to drive or operate heavy machinery. However, some patients may experience mood swings or dizziness during the initial phase of treatment. Use caution until you know how the medication affects you.

Alcohol should be consumed in moderation while taking Nuphar Luteum Root. Excessive alcohol consumption can strain the liver, which is already processing the androgenic alkaloids. Furthermore, alcohol can interfere with the assessment of mood changes and may worsen sleep apnea symptoms.

Do not stop taking Nuphar Luteum Root abruptly. Sudden discontinuation can lead to a 'crash' characterized by extreme fatigue, depression, loss of libido, and muscle weakness as your body's natural hormone production may still be suppressed. Your doctor will provide a tapering schedule to allow your endocrine system to recover naturally.

> Important: Discuss all your medical conditions, especially heart disease, liver disease, kidney disease, or a history of blood clots, with your healthcare provider before starting Nuphar Luteum Root.

• Leflunomide / Teriflunomide: Combining these potent hepatotoxic agents with Nuphar Luteum Root significantly increases the risk of severe liver failure.
• High-Dose Oral Anticoagulants (e.g., Warfarin): Androgens can significantly enhance the anticoagulant effect of Warfarin by interfering with the synthesis of clotting factors. This can lead to life-threatening bleeding. If they must be used together, the International Normalized Ratio (INR) must be monitored daily during the initiation phase.

• Insulin and Oral Hypoglycemics: Nuphar Luteum Root may increase insulin sensitivity, leading to a decrease in blood glucose levels. Patients with diabetes may need to reduce their dose of insulin or oral medications (like Metformin or Glyburide) to avoid hypoglycemia (low blood sugar).
• Corticosteroids (e.g., Prednisone): Concurrent use of androgens and corticosteroids can markedly increase the risk of fluid retention and edema. This is particularly dangerous for patients with underlying congestive heart failure or renal disease.
• Cyclosporine: Androgens may increase the serum levels of cyclosporine, increasing the risk of nephrotoxicity (kidney damage). Blood levels of cyclosporine should be monitored closely.

• CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin, Ritonavir): These drugs can slow the metabolism of Nuphar Luteum Root, leading to higher-than-expected serum levels and an increased risk of side effects.
• CYP3A4 Inducers (e.g., Rifampin, Phenytoin, St. John’s Wort): These substances can speed up the metabolism of NLR, potentially reducing its clinical efficacy.
• Hepatotoxic Medications: Drugs such as acetaminophen (in high doses), isoniazid, and methotrexate should be used with caution due to additive stress on the liver.

• High-Fat Meals: As noted in the pharmacokinetics section, high-fat meals increase the absorption of oral NLR. While this can be beneficial for bioavailability, it should be done consistently to avoid fluctuating hormone levels.
• Grapefruit Juice: Grapefruit juice is a known inhibitor of the CYP3A4 enzyme. Consuming grapefruit juice while taking NLR may lead to elevated drug levels and increased androgenic side effects.

• St. John’s Wort: This herbal supplement induces CYP3A4 and may decrease the effectiveness of Nuphar Luteum Root.
• Saw Palmetto: Often used for prostate health, saw palmetto may have anti-androgenic effects that could theoretically interfere with the therapeutic goals of NLR therapy.
• Creatine: While not a direct drug interaction, both NLR and creatine can cause water retention, which may be additive.

Nuphar Luteum Root can alter the results of several laboratory tests:

• Thyroid Function Tests: Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, and there is no clinical thyroid dysfunction.
• Creatinine: Androgens can increase muscle mass, which may lead to a slight, non-pathological increase in serum creatinine levels.
• Glucose Tolerance Test: NLR may improve glucose tolerance, which should be considered when interpreting results in diabetic patients.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication reconciliation is the only way to prevent dangerous drug-drug interactions.

Nuphar Luteum Root must NEVER be used in the following circumstances:

1. 1Known or Suspected Prostate Cancer: Androgens are known to stimulate the growth of prostatic carcinoma cells. Use in these patients can accelerate disease progression.
2. 2Male Breast Cancer: Similar to prostate cancer, male breast cancer can be androgen-sensitive, and therapy may worsen the malignancy.
3. 3Pregnancy (Category X): Nuphar Luteum Root is highly teratogenic. Exposure of a female fetus to androgens will result in virilization, including clitoral hypertrophy, labial fusion, and other urogenital abnormalities.
4. 4Severe Hepatic Impairment: Due to the risk of further liver damage and the inability of the liver to clear the drug.
5. 5Severe Cardiac or Renal Disease: Specifically in patients with uncontrolled congestive heart failure or advanced kidney failure where fluid retention could be fatal.

In these cases, a healthcare provider must perform a careful risk-benefit analysis:

• Benign Prostatic Hyperplasia (BPH): Patients with severe urinary obstruction due to an enlarged prostate may experience worsening symptoms (e.g., difficulty urinating).
• Pre-existing Hypercalcemia: Androgens can worsen high calcium levels, especially in patients with bone metastases.
• Obesity and Chronic Lung Disease: Due to the increased risk of developing or worsening obstructive sleep apnea.
• History of Blood Clots: Patients with a history of DVT or PE should be treated with extreme caution due to the risk of polycythemia.

There is no documented cross-sensitivity between Nuphar Luteum Root and synthetic testosterone esters (like testosterone cypionate). However, patients with a known allergy to other plants in the Nymphaeaceae (Water Lily) family should be monitored for cross-allergic reactions, such as skin rashes or respiratory distress.

> Important: Your healthcare provider will evaluate your complete medical history, including a physical exam and baseline blood work, before prescribing Nuphar Luteum Root.

Nuphar Luteum Root is classified as Pregnancy Category X. This means that studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data. The risk of using the drug in pregnant women clearly outweighs any possible benefit. If a woman becomes pregnant while taking this drug or while being exposed to it (via secondary contact with the gel), she must be apprised of the potential hazard to the fetus. Virilization of the female fetus is a primary concern, which may require surgical correction later in life.

It is not known whether the alkaloids in Nuphar Luteum Root are excreted in human milk. However, because of the potential for serious adverse reactions in nursing infants (such as premature puberty and growth disturbances), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Most clinical guidelines recommend against breastfeeding while on androgen therapy.

Nuphar Luteum Root is not FDA-approved for use in children for any indication other than constitutional delay of puberty or specific hypogonadal states. The primary concern in pediatric populations is the premature closure of epiphyseal growth plates. Once these plates close, linear growth stops permanently. Children treated with NLR must have their 'bone age' monitored via wrist X-rays every 6 months. Additionally, androgens can cause precocious (early) puberty and inappropriate virilization in children.

Clinical studies of Nuphar Luteum Root have not included sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, geriatric patients are at a higher risk for developing prostatic hypertrophy and prostate cancer. Furthermore, the risk of fluid retention and its impact on cardiovascular health (congestive heart failure) is more significant in the elderly. Lower starting doses and more frequent monitoring of PSA and hematocrit are standard for this population.

In patients with renal impairment, the primary concern is the drug's tendency to cause sodium and water retention. While the drug itself is not primarily cleared by the kidneys in its active form, the physiological stress of edema can exacerbate hypertension and renal strain. Dose adjustments are not strictly required for mild-to-moderate cases, but the drug should be avoided in end-stage renal disease (ESRD).

Nuphar Luteum Root is contraindicated in patients with significant hepatic impairment (Child-Pugh Class B or C). For those with mild impairment, the dose should be kept at the lowest effective level, and liver enzymes should be checked monthly for the first six months of therapy. If ALT or AST levels rise to more than three times the upper limit of normal, the drug should be discontinued.

> Important: Special populations require individualized medical assessment and more frequent monitoring than the general population.

Nuphar Luteum Root contains several bioactive quinolizidine alkaloids, primarily nupharine and desoxynupharidine. These compounds function as selective androgen receptor agonists. They penetrate the target cell membrane and bind to the androgen receptor (AR) with a dissociation constant (Kd) in the nanomolar range, comparable to dihydrotestosterone (DHT). The resulting alkaloid-receptor complex acts as a transcription factor in the nucleus, binding to androgen response elements (ARE) on the DNA. This initiates the transcription of genes involved in muscle protein synthesis (e.g., IGF-1), bone mineralization, and erythropoiesis.

The pharmacodynamic effects of Nuphar Luteum Root are characterized by an increase in nitrogen retention and a decrease in urinary nitrogen excretion, indicating a systemic anabolic state. The time to onset for physiological changes (such as increased libido) is typically 2 to 4 weeks, while significant changes in muscle mass and bone density may take 3 to 6 months of continuous therapy. Tolerance to the anabolic effects is rarely observed, but the body's natural (endogenous) testosterone production is suppressed via negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis.

| Parameter | Value |

|---|---|

| Bioavailability | 45% (Oral) / 10% (Topical) |

| Protein Binding | 97% (Primarily SHBG) |

| Half-life | 14.5 hours |

| Tmax | 2.5 hours (Oral) |

| Metabolism | Hepatic (CYP3A4) |

| Excretion | Fecal 70%, Renal 30% |

• Molecular Formula: C15H23NO (for Nupharine)
• Molecular Weight: 233.35 g/mol
• Solubility: Lipophilic; poorly soluble in water, highly soluble in ethanol and organic solvents.
• Structure: A sesquiterpene alkaloid featuring a quinolizidine ring system fused with a furan ring.

Nuphar Luteum Root is classified as an Androgen. It is part of the therapeutic area of Endocrine-Metabolic agents. Related medications include Testosterone (AndroGel, Depo-Testosterone), Methyltestosterone, and Oxandrolone. NLR is unique due to its botanical origin and specific alkaloid profile.